FDA Approves Generic Depressive Disorder Drug
Cymbalta is also indicated to treat general anxiety disorder in adults and children, fibromyalgia, or chronic muscle or joint pain, such as low back pain and osteoarthritis.
Officials with Solco Healthcare US announced that the FDA approved its generic equivalent of Cymbalta capsules (Duloxetine delayed-release capsules), 20-mg, 30-mg and 60-mg. The product is available now.
Duloxetine is used to treat major depressive disorder in adults. Duloxetine is also used to treat general anxiety disorder in adults and children who are at least 7 years old. Duloxetine may be used in adults to treat fibromyalgia, or chronic muscle or joint pain, such as low back pain and osteoarthritis pain.
"We are pleased to receive this FDA approval, which adds to our growing line of central nervous system acting agents. We continue to strengthen our presence within the US generic market by providing high quality medicines at affordable prices,” Hai Wang, President of Solco Healthcare said in a press release.
According to QuintilesIMS, US brand and generic sales of duloxetine delayed-release capsules were approximately $484.4 million for the 12 months ending in June 2017.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025